COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

HHS Invokes Defense Production Act to Speed SARS-CoV-2 Antigen Test Production

Covid-19 rapid response
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Wartime law set to increase production volumes of POC COVID-19 tests.

On Aug. 20, 2020, the US Department of Health and Human Services (HHS) announced it would invoke the Defense Production Act (DPA) to apply priority-rated orders for SARS-CoV-2 antigen testing contracts. The contracts that are receiving prioritization are with Becton Dickinson (BD) and Quidel Corporation—the two established manufacturers of diagnostic SARS-CoV-2 antigen tests. A third rapid antigen test by LumiraDx had received an emergency use authorization (EUA) two days before the HHS announcement.

According to the HHS statement, “These acquisitions will fulfill a large-volume purchase of diagnostic systems and assays for COVID-19 testing and will expedite shipments of these systems and assays to every nursing home certified by the Centers for Medicare and Medicaid Services (CMS) with a Clinical Laboratory Improvement Amendment (CLIA) Certificate of Waiver—approximately 14,000 nursing homes—in the United States.”

Assistant Secretary for Health and COVID-19 Testing Coordinator Admiral Brett P. Giroir, MD, issued a statement regarding this announcement. “The federal efforts to supply nursing homes with rapid point-of-care antigen instruments and tests is our highest priority to save lives and the US Government will exert its full authority to complete this mission,” Giroir said in the announcement. “We are invoking the priority rating of the Defense Production Act to expedite shipments of instruments and antigen tests to give nursing homes the ability to perform these rapid tests. HHS will continue to explore every possible avenue to get life-saving supplies to the frontlines of this war on the virus.”

Related Resources:

HHS Release: Trump Administration Uses Defense Production Act to Aid Our Most Vulnerable

Becton Dickinson (BD)

Quidel Corporation


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group